Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303102 | 0.79 | PARP1 (0.49) | PARP1ADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL28986906 | 0.79 | PARP1 (0.49) | PARP1ADORA3ADORA2AADORA1ATAD2 | |
| SCHEMBL28893532 | 0.79 | PARP1 (0.49) | PARP1ADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL3817890 | 0.79 | PARP1 (0.49) | PARP1ADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL1681360 | 0.78 | PARP1 (0.45) | PARP1ADORA3ADORA2AADORA1ATAD2 | |
| SCHEMBL18237558 | 0.78 | PARP1 (0.45) | PARP1ADORA3ADORA2AADORA1ATAD2 | |
| SCHEMBL1326106 | 0.77 | PARP1 (0.44) | PARP1ADORA3ADORA2AADORA1ATAD2 | |
| SCHEMBL26136040 | 0.72 | ADORA3 (0.41) | PARP1ADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL4261079 | 0.72 | GSK3B (0.38) | KDM4EMAPTAURKA | |
| SCHEMBL30293081 | 0.72 | ALDH1A1 (0.58) | PARP1ADORA3KDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2074122-B9 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PROD INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2074122-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2074122-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008032162-A8 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008032162-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032162-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PARP1 2195/4885ADORA3 4145/4885ADORA2A 4582/4885 |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | PARP1 1586/4885ADORA3 2916/4885ADORA2A 2779/4885 |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PARP1 559/4885ADORA3 2208/4885ADORA2A 2997/4885 |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PARP1 559/4885ADORA3 2208/4885ADORA2A 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.